Clinical Trial Update: Pre-emptive Anakinra for Cytokine Event Reduction [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating pre-emptive anakinra to reduce cytokine release syndrome and related neurotoxicity in CAR-T cell therapy for B-cell acute ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Anakinra (anakinra)

Snippet

Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago | Conditions: B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING